Module 5: Monitoring and Evaluation
Aberrant drug-related behaviour (cont’d)
Additional aberrant drug-related behaviours can be found on the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain, appendix B-10. Principles related to opioids as an example may be generalizable to behaviours with other controlled substances.
If a prescriber is concerned about aberrant drug behaviour, a validated tool such as the SOAPP-R for assessment may be considered. The SOAPP-R is an instrument that can help clinicians identify patients who may require extra monitoring and management (Michna et al., 2004).
- Michna, E., Ross, E. L., Hynes, W. L., Nedeljkovic, S. S., Soumekh, S., Janfaza, D., Palombia, D., & Jamison, R.N. (2004). Predicting Aberrant Drug Behavior in Patients Treated for Chronic Pain: Importance of Abuse History. Journal of Pain Symptom Management, 28(3), 250–258. doi:10.1016/j.jpainsymman.2004.04.007
- NOUGG. (2017). Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain — Appendix B-10. Retrieved from http://nationalpaincentre.mcmaster.ca/opioid/cgop_b_app_b10.html